Suffering Eleven Bio gets a delisting notice from Nasdaq

After back-to-back clinical disasters pushed Eleven Biotherapeutics ($EBIO) into penny stock territory, Nasdaq says it's time to get squared away or move off the exchange. The Cambridge, MA-based biotech addressed the delisting notice from Nasdaq in an SEC filing, noting that its stock is trading under $1 a share and that stockholders' equity did not comply with the minimum stockholders' equity requirement of $5,000,000. The biotech now has 180 days to regain compliance with Nasdaq rules. SEC filing

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.